anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The potential toxicity of BPQDs has received considerable attention due to their increasing use in biomedical applications. In this study, the toxicity of BPQDs at concentrations of 5 μg/mL, 50 μg/mL, and 500 μg/mL on the brain-gut axis was assessed in zebrafish. Following 35 days of exposure, the neurotransmitter, locomotor behavior, gut barrier (physical barrier, chemical barrier, and microbial barrier), and gut content metabolism in zebrafish were evaluated. The results indicated that BPQDs induced the locomotor behavior abnormalities, inhibited acetylcholinesterase activity, induced dopaminase activity, and promoted apoptosis in zebrafish brain tissue. Meanwhile, BPQDs caused damage to the physical and chemical barriers in zebrafish intestinal tissue, which increased the permeability of the intestinal mucosa, and induced oxidative stress and apoptosis. The gut microbiota was analyzed by 16S rRNA gene sequencing. The results showed that BPQDs caused dysbiosis of the gut microbiota, resulting in decreased diversity. Specifically, the relative abundance of Firmicutes, Bacteroidetes, and Actinobacteria decreased, while the relative abundance of Proteobacteria and Clostriobacteria increased. At the genus level, the high concentration BPQDs showed a significant increase in Cetobacterium, Pleisionomas, Aeromonas, and other bacteria. Bioinformatic analysis revealed a correlation between the relative abundance of the gut microbiota and antioxidant levels, immune response, and apoptosis. Statistical analysis of the metabolomic revealed significant perturbations in several metabolic pathways, including amino acid, lipid, nucleotide, and energy metabolism. In addition, correlation analysis between microbiota and metabolism confirmed that gut microbiota dysbiosis was closely associated with metabolic dysfunction. The histopathologic injury supported the changes in biomarkers and the expression of related marker genes in the gut-brain axis, indicating the communication between the gut peripheral nerves and the CNS. The results indicate that BPQDs induce gut microbiota dysbiosis, disrupt metabolic function, and induce neurotoxicity, probably by disrupting the homeostasis of the microbiota-gut-brain axis. In summary, this study demonstrates the effects of BPQDs on physiological changes within the zebrafish brain-gut axis and provides valuable data for assessing the toxicological risks of BPQDs in aquatic ecosystems.
The invention provides a method for preparing a traditional Chinese medicine lotion for treating hypothermia type frostbite, which belongs to the technical field of methods for preparing traditional Chinese medicines. At present, sulfonamides and antibiotics are used for treating hypothermia type frostbite in general. If sulfamethoxazole is used, gastrointestinal tract reaction, crystalluria, bloody urine, rash, drug fever and leukopenia are caused. The invention adopts the technical scheme that the method comprises the steps of: taking radix aconiti carmichaeli, asarum, black pepper, long pepper, piper cubeba, funnel, leek, galangal, cnidium fruit, chilli, caraway, aromatic ginger, monkshood root, earthworm, stiff silkworm, scorpion, centipede, schizonepeta, ledebouriella root, angelica root, dried ginger and licorice root; putting 23 Chinese medicinal herbs in water, soaking, then decocting with mild fire and filtering to remove dregs; and obtaining decocted liquid as the traditional Chinese medicine lotion for treating hypothermia type frostbite. The invention has the advantages that the prepared traditional Chinese medicine liquid has small toxic side effect, short therapeutic course and high therapeutic rate, and the main Chinese medicinal herbs and the auxiliary Chinese medicinal herbs are perfectly matched. When the traditional Chinese medicine is used, adverse reaction, anaphylactic reaction and toxic reaction which are caused by western medicines, such as sulfonamide and antibiotics are avoided.
Each capsule contains 3.70 megabecquerels (100 microCi) at time of calibration. Half of each capsule is white, while the other half is either pink, yellow, orange, grey or green according to the manufactured lot.

  * The capsules are packaged in plastic vials containing 5 capsules of the same strength and same color. (NDC 65174-461-05).
  * Consult the color-coded decay calendar that is updated in January of each year to help you establish which colored capsules correspond to your prescribed dose: https://www.draximage.com/products/us/draximage-i-131-diagnostic-capsules/ or calculate the correct dosage from the date and time of calibration provided on the container label.
  * The calibration date and expiration date are indicated on the vial container label.
Seizure semiology and electroencephalograph (EEG) are very important for determining seizure type, hemisphere lateralization, or localization. Clinical symptoms of focal seizures, as well as findings at the onset or end of a focal to bilateral tonic-clonic seizure (FBTCS), are highly informative for lateralization. This study aimed to investigate the relationship of asymmetric last clonic jerk in patients with temporal or extratemporal lobe epilepsy with pathologies, localization, lateralization, or other semiological findings detected in neuroimaging or neuro psychometric tests and its positive predictive value for the detection of hemisphere lateralization based on seizure onset ictal EEG activation. 44 patients with asymmetric last clonic jerks (aLCJ) who were followed up in our VEM unit were randomized 1:1 with epilepsy patients without. In patients with ipsilateral automatism and contralateral posture or gustatory and olfactory hallucinations aLCJ was less or absent. In patients with unilateral tonic activity, aLCJ was more common. The positive predictive value of aLCJ for ictal EEG activation lateralization was 86.36%. In conclusion, asymmetric last clonic beat is valuable for lateralization of FBTCS and should be considered. Its presence strongly and reliably lateralizes to the side of seizure onset.
As the transporter responsible for basal levels of glucose flux, Glucose transporter 1 (GLUT1) is expressed at low levels in most tissues. In contrast, GLUT1 is very highly expressed on human erythrocytes. Human erythrocytes possess up to 5x105 copies of GLUT1 in their membranes representing almost 5% of total membrane protein. This allows erythrocytes to catalyze glucose transfer at rates three orders of magnitude greater than their capacity to utilize it. It has been proposed that human erythrocytes function in glucose storage, especially when the serum carrying capacity for glucose becomes limiting. If this hypothesis could be validated experimentally, it would be of fundamental importance to the understanding of human physiology.

This proposal also has the potential to uncover a novel therapeutic option for patients with Glucose Transporter Type 1 Deficiency (G1D). Currently, the only treatment for G1D is the ketogenic diet. While the ketogenic diet improves seizures in a fraction of patients, its effects on neurodevelopment and long-term health are poor, so better treatment options for G1D are needed. Because of the hypoglycorrachia (i.e. low cerebrospinal fluid glucose) of G1D patients, the endothelial cells of the blood-brain barrier microvessels have long been assumed to be the primary site of disease pathogenesis. However, most G1D patients also have deficits in GLUT1 levels and glucose uptake in their erythrocytes and a potential contribution of this compartment to disease pathogenesis is likely. GLUT1 deficient mice are not amenable to test the hypothesis because they do not fully recapitulate the clinical presentation of G1D patients and because they exhibit metabolic adaption to G1D. Red blood cell exchange (RBCx) is a safe and cost effective treatment to prevent strokes and vascular abnormalities in patients with sickle cell anemia. RBCx has the potential to dramatically alter the treatment of G1D patients.
Compliance (which refers to how well one follows a prescribed medication or therapy) varies among all types of diseases, but it is generally low for those outpatients with major mental illness. This leads to relapses and worsening of their condition, and worsening of their condition may lead to poor compliance. The purpose of the study is to record, analyze, and report how well patients with major mental illness in an outpatient setting follow the prescribed treatment plan for the first few months of a new treatment strategy (either a first-time therapy plan or a change to a therapy plan). Therapy plans include psychiatric counseling (psychotherapy), visits to the outpatient clinic, and taking prescribed drugs. "Compliance" is defined as actually doing what the plan says, including attending therapy sessions, going for clinic visits, and taking necessary medication. The study will look for individual factors for each patient that might influence lack of compliance, and then see whether some of the individual factors predict a lack of compliance in the group as a whole, which includes approximately 2500 patients. These factors include a diagnosis of schizophrenia compared with a diagnosis of another major mental illness such as depression, bipolar disorder, or personality disorder. Social and personal factors will also be recorded and analyzed to see whether they influence the patient's ability to follow the treatment plan. Examples are age, sex, education, race, urban versus rural lifestyle, family supportiveness, and substance abuse status. Other factors to be studied that may vary between patients who are either good, average, or poor at following their treatment plan include the number of hospital admissions for each patient, how long it has been since their last hospitalization, and the reason why their new therapy plan was changed or started. The study will also try to determine how physicians confirm the patient's reports of their adherence to their treatment plan. A physician may take blood to measure levels of the drug, count a patient's pills or injections, or simply ask the patient or a family member. Researchers will compare compliance when different classes of drugs are prescribed, such as antidepressants and antipsychotics, to determine whether a particular group of drugs is associated with improved compliance. The safety and effectiveness of the drugs prescribed might also influence whether patients take their medication, so these factors will be evaluated. Adverse events (unintended and undesirable effects that might be due to the treatments) will be recorded for each patient over the 3 months of the study, and the physician will record the results of a Global Clinical Impression scale that ranges from "No Illness" to "Extreme Illness" to record an overall impression of the patient's illness before and after treatment. Antipsychotics and antidepressants, as used in routine clinical practice. Study duration is 3 months.
The invention relates to a life cultivation and health preservation pillow which comprises a pillowcase and a pillow interior. A plurality of inflatable bags are arranged between the pillowcase and the pillow interior. The pillowcase is provided with two cloth layers. The outer cloth layer is arranged to be a rough face, and the inner cloth layer is arranged to be a smooth face. One side edge of the pillowcase is provided with a zipper. Magnets are arranged between the inflatable bags and the pillow interior. Plastic flexible packages are arranged outside the magnets. A plurality of layers of liquid bags are arranged inside the pillow interior. A package bag containing traditional Chinese medicine powder is arranged between every two adjacent layers of liquid bags. The Chinese herbal medicinal ingredients contained in the package bags are composed of rhizoma atractylodis, rhizoma acori graminei, Ligusticum wallichii, radix angelicae pubescentis, mentha haplocalyx, schizonepeta, folium artemisiae argyi, purple perilla, radix angelicae, syzygium aromaticum, cassia twigs, rhizoma nardostachyos, poria cocos, radices sileris, borneol, camphor, peach kernels, safflower carthamus, angelica sinensis, radix clematidis, chrysanthemums, eupatorium and mangnolia officinalis. According to the life cultivation and health preservation pillow, due to the arrangement of the magnets and the various life cultivation and health preservation Chinese herbal medicinal ingredients, the human sleep can be well adjusted, and the human immunity can be enhanced.
The invention relates to medicine for treating lupus nephritis. The medicine is prepared from, by weight, 15 parts of woody hawkbeard roots, 12 parts of roots of pecteilis susannae (L.) rafin., 10 parts of saxifraga, 25 parts of thatch screwpine roots, 12 parts of tender catchweed bedstraw herbs, 15 parts of all-grass of tripterospermum affine (wall.) H. Smith, 6 parts of myricaria bracteata royle twigs, 9 parts of fruits or roots of rubus coreanus miq. and 10 parts of leaves or roots of tragopogo porrifolius L.. According to the medicine, the woody hawkbeard roots are used for restoring the kidney, clearing heat, draining dampness and eliminating carbuncle; the roots of pecteilis susannae (L.) rafin are used for invigorating the kidney, strengthening yang, soothing the liver and dispelling cold; the saxifraga is used for replenishing qi and blood, dredging main and collateral channels and mainly aims at treating the symptoms of qi deficiency and blood deficiency; the thatch screwpine roots are used for reducing fever, causing diuresis and inducing perspiration; the tender catchweed bedstraw herbs are used for clearing away head and toxic materials and inducing diuresis for treating stranguria; the all-grass of tripterospermum affine (wall.) H. Smith is used for cooling blood for hemostasis, inducing diuresis and removing toxic materials; the myricaria bracteata royle twigs are used for removing toxic materials, invigorating yang and conducting divergence; the fruits or roots of rubus coreanus miq. are used for tonifying the kidney and qi; the leaves or roots of tragopogo porrifolius L. are used for invigorating the spleen and supplementing qi. All the medicinal materials are combined to be used and jointly achieve the effects of clearing away heat and toxic materials, nourishing the liver and the kidney, invigorating blood circulation, inducing diuresis and tonifying qi. Clinical experiments indicate that by means of the medicine, lupus nephritis can be treated safely and effectively.
Participants will receive sham stimulation for 30 minutes prior conventional physical therapy program. They will be asked to perform this combination therapy for 15 sessions, occurring three times a week for five weeks.
This aim of this study is to determine the safety and efficacy of adult allogeneic bone marrow derived mesenchymal stem cells (MSCs), for the treatment of medically refractory peri-pouch fistulizing disease in the setting of Crohn's disease of the pouch. The study will randomize 20 participants. Enrolled participants will be randomized to treatment group with MSCs, versus placebo in a 3:1 fashion. Participants in the treatment group will have a direct injection of MSCs at a dose of 75 million cells. This will be given as a direct injection in and around the fistula tract. Participants will be evaluated for complete healing at three months. If complete healing has been achieved participants will continue to be followed for one year. If complete healing has not been achieved at three months, participants will be eligible for a second injection of MSCs at the same dose of 75 million cells. Control participants without complete healing from placebo will cross over at the 6 month visit to receive an injection of MSCs and will be followed for one year after treatment to a total duration of 18 months. The primary efficacy analysis will be conducted at the month 6 time point.
1472427 Process for alkali metal or ammonium insulin ELI LILLY & CO 15 July 1974 [16 July 1973] 31199/74 Heading C3H Alkali metal insulin or ammonium insulin is prepared by a process which comprises (A) preparing an alkaline aqueous solution of a divalent metal insulin, a chelating agent for divalent metal ions, and alkali metal or ammonium ions, wherein the divalent metal is selected from the elements of Groups VIIB, VIII, IB and IIB of the Periodic Table of the elements, the concentration of divalent metal insulin is 10 to 1000 U/mg., the concentration of alkali metal or ammonium ions is 0À2 to 1À0 M, the pH of the solution is 7À6 to 8À6, the concentration of chelating agent is 0À0002 to 0À05 M, the molar ratio of chelating agent to divalent metal in the divalent metal insulin is at least 3 : 1, and the chelating agent has the general formula wherein R 1 , R 5  are monovalent organic radicals independently selected from carboxymethyl, carboxyethyl, C 1-6  alkyl, C 1-6  hydroxyalkyl; R 2  and R 6  are monovalent organic radicals independently selected from carboxymethyl, carboxyethyl; R 3  is a monovalent radical selected from hydrogen, hydroxy, C 1-6  alkyl; R 4  is a monovalent radical selected from hydrogen, carboxymethyl, carboxyethyl; m is 1 to 6; n is 0 or 1; p is 0 or 1, r is 2-6; s is 0 to 2; (B) crystallizing the alkali metal insulin or ammonium insulin. The preferred divalent metal is manganese, iron, cobalt, nickel, copper, zinc or cadmium and the preferred alkali metal is sodium. The preferred chelating agent is EDTA. The divalent metal insulin may contain 0 to 0À4% weight per volume of a preservative, such as phenol. Examples describe the preparation of (1)-(3) sodium insulin, (4) potassium insulin, (5) lithium insulin and (6) ammonium insulin. Polyacrylamide gel electrophoretic analysis indicates that the sodium insulin of Examples (2) and (3) is free from non-insulin proteins which are present in the starting material, sodium insulin, isolated from pork pancreas.
An antibacterial fluid may be applied to a tubular medical cannula for access to a patient. The fluid comprises a typically metabolizable antibacterial formulation having a viscosity preferably greater than 150,000 cp. The cannula may then be inserted into the patient with an increased lubricity for a reduction of pain, while at the same time, unlike silicones, preferred materials do not readily accumulate in the patient. The fluid may be placed on the skin. The tubular medical cannula may be a rigid, hollow needle, sharp or blunt, a spike, or a flexible catheter. Also, the viscous antibacterial fluid may be used to lock a catheter or other cannula while implanted in the patient, for storage purposes. The formulation is typically an alcohol plus a viscosity increasing agent and optionally a surfactant, a clotting agent, and/or EDTA.
This group included the participants who received at least one dose of CAB LA and/or RPV LA and discontinued the CAB LA + RPV LA regimen for any reason before end of Maintenance Period. The participants entered a 52-week LTFU period.
Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by instability of the tear film and the prevalence has been estimated to reach 20%-40%. Especially, dry eye symptoms are common complaints of patients with blepharospasm or refractive surgery history, seriously affecting their quality of life. There are many conventional therapies for DED which include ocular lubricants, oral essential fatty acid supplementation, lid hygiene and warm compresses, punctal occlusion, various treatments to obstructed meibomian glands, topical antibiotics, topical corticosteroids, topical secretagogues, topical non-glucocorticoid immunomodulatory drugs and scleral contact lenses. However, the overall efficacy is still unsatisfactory with apparent side effects, long periods of treatment, and high-costs. Mesenchymal stem cell-derived exosomes (MSC-Exo) are 30-150nm microvesicles secreted by mesenchymal stem cells (MSCs), which can mediate the therapeutic efficacy of mesenchymal stem cells by the encapsulated proteins, miRNAs and other bioactive substances, and showed potential in the treatment of various diseases. This study aims to evaluate the preliminary safety and effectiveness of PSC-MSC-Exo in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm.

This is an open-label, single-arm, before-after study with 12 subjects with dry eye diseases and the history of refractive surgery or blepharospasm. There are 5 visits over the course of 12 weeks. Visit 1: Week-1 Visit 2: Week-2 Visit 3: Week-4 Visit 4: Week-8 Visit 5: Week-12
Disclosed herein are compositions (e.g., sprays, paints, etc.) that comprise antimicrobial zeolite nanoparticles. Also provided are hemostatic compositions comprising zeolite nanoparticles, dryer sheets comprising zeolite nanoparticles, and textiles comprising zeolite nanoparticles. Also disclosed are compositions (e.g., sprays) that include a binder polymer to improve coating adherence. In some cases, the zeolite nanoparticles can further comprise an optical tracer (e.g., a fluorophore) associated with the zeolite nanoparticles. The optical tracer can be interrogated to confirm presence of the zeolite nanoparticles (or a coating comprising the zeolite nanoparticles) on a surface. Also provided are methods of forming viricidal coatings using compositions that comprise zeolite nanoparticles dispersed in a carrier.
• Stop Nexesta Fe if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.

• Stop Nexesta Fe if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.

• If feasible, stop Nexesta Fe at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during the following prolonged immobilization.

• Start Nexesta Fe no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

• The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.

  


Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). The risk increases with age, particularly in women over 35 years of age who smoke.

• Use COCs with caution in women with cardiovascular disease risk factors.